Tag: Array Biopharma

Finance

NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished the day at $4.92. Traded volume was 3.02million shares in … Continue reading NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

John Meady
Finance

Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova Therapeutics Inc (NASDAQ:ONTX) for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova Therapeutics Inc (NASDAQ:ONTX) has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get … Continue reading Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

Mark Doerr
BioTech, Stock Movers

Array Biopharma (NASDAQ:ARRY) Jumping Pre-Bell, SolarCity (NASDAQ:SCTY), Nu Skin Enterprises (NYSE:NUS) Slip

Array BioPharma (NASDAQ:ARRY) was up more than 9% in pre-market trade after reporting positive study results for its asthma treatment. The company said, ARRY-502, an oral CRTh2 antagonist, was studied in a 184-patient placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma, a population representing more than 12 million patients in the U.S. ARRY-502 met the primary endpoint in the trial, … Continue reading Array Biopharma (NASDAQ:ARRY) Jumping Pre-Bell, SolarCity (NASDAQ:SCTY), Nu Skin Enterprises (NYSE:NUS) Slip

John Meady